Novo Nordisk NVO is scheduled to report its second-quarter 2025 results before the opening bell on Aug. 6, 2025. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $11.79 billion, while the same for earnings is pinned at 93 cents per share.
In the past 60 days, the Zacks Consensus Estimate for Novo Nordisk’s 2025 earnings per share (EPS) improved from $3.84 to $3.86. During the same time frame, the company’s 2026 EPS forecast has dropped from $4.64 to $4.20.
Image Source: Zacks Investment Research
Novo Nordisk’s performance has been mixed over the trailing four quarters, with earnings beating estimates in one quarter, matching once and missing the mark on the remaining two occasions. On average, Novo Nordisk registered an earnings surprise of 0.02% in the trailing four quarters. In the last reported quarter, the company reported EPS that matched estimates.
Image Source: Zacks Investment Research
Novo Nordisk has an Earnings ESP of +0.22% and a Zacks Rank #4 (Sell) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1, #2 (Buy) or #3 (Hold) have a good chance of delivering an earnings beat, which is not the case for NVO. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Novo Nordisk operates under two segments — Diabetes and Obesity Care and Rare disease.
Novo Nordisk reported preliminary earnings per American Depositary Receipt of 91 cents (DKK 5.96) for the second quarter of 2025. During the same period, the company’s sales increased 18% at constant exchange rate (CER). On the other hand, operating profit increased 40% at CER in the second quarter of 2025, primarily driven by the ocedurenone impairment charge recognized in the year-ago period.
Novo Nordisk’s revenues are expected to have been driven by the sale of its diabetes and obesity treatments, particularly semaglutide-based drugs — Wegovy, Ozempic, and Rybelsus. Wegovy is the largest contributor to the company’s top line. Its label has also been expanded for cardiovascular benefits in the United States and the EU. Ozempic and Rybelsus sales are also likely to have contributed meaningfully, along with solid insulin product sales. Additionally, the Rare Disease segment is expected to have generated incremental revenues for the company.
Read More: How Should Investors Play the Stock?
